Utility of gallium67 scintigraphy and bronchial washings in the diagnosis and treatment of Pneumocystis carinii pneumonia in patients with the acquired immune deficiency syndrome. NLM AIDSLINE Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Utility of gallium67 scintigraphy and bronchial washings in the diagnosis and treatment of Pneumocystis carinii pneumonia in patients with the acquired immune deficiency syndrome.

Am Rev Respir Dis. 1985 Nov;132(5):1087-92. Unique Identifier : AIDSLINE MED/86048867
Tuazon CU; Delaney MD; Simon GL; Witorsch P; Varma VM

Abstract: Twenty patients with the acquired immune deficiency syndrome (AIDS) and suspected Pneumocystis carinii pneumonia were evaluated by gallium67 (Ga67 scintigraphy and fiberoptic bronchoscopy for initial diagnosis and response to therapy. Lung uptake of Ga67 was demonstrated in 100% of AIDS patients with P. carinii pneumonia, including those with subclinical infection. Fiberoptic bronchoscopy identified P. carinii in the bronchial washings of 100% of cases (19 patients), whereas only 13 of 16 (81%) patients had P. carinii in lung tissue obtained by transbronchial biopsy. Repeat fiberoptic bronchoscopy was performed in 16 of 20 patients. After 2 to 4 wk of therapy, P. carinii was identified in bronchial washings in 8 of 16 (50%) patients and in transbronchial biopsy in 1 of 10 (10%) patients examined. Bronchial washing has a higher yield than transbronchial biopsy in demonstrating P. carinii in patients with AIDS and may evolve as the procedure of choice in such patients. Based on the clinical course and results of Ga67 scintigraphy and fiberoptic bronchoscopy in AIDS patients with P. carinii pneumonia, optimal therapy may require at least 3 wk of treatment.
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Adult Biopsy Bronchi/*PARASITOLOGY Bronchoscopy Drug Combinations/THERAPEUTIC USE Gallium Radioisotopes/*DIAGNOSTIC USE Human Middle Age Pentamidine/THERAPEUTIC USE Pneumocystis carinii/ISOLATION & PURIF Pneumonia, Pneumocystis carinii/*DIAGNOSIS/DRUG THERAPY/ RADIONUCLIDE IMAGING Sulfamethoxazole/THERAPEUTIC USE Trimethoprim/THERAPEUTIC USE JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/KWDcomplicationsadultbiopsybronchi/KWDparasitologybronchoscopydrugcombinations/therapeuticusegalliumradioisotopes/KWDdiagnosticusehumanmiddleagepentamidine/therapeuticusepneumocystiscarinii/isolation&purifpneumonia,pneumocystiscarinii/KWDdiagnosis/drugtherapy/radionuclideimagingsulfamethoxazole/therapeuticusetrimethoprim/therapeuticusejournalarticle
860228
M8620135

Copyright © 1986 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .